Table 2. Survival Analysis of Factors Associated With Altered PFS and OS in Patients With AEOC Receiving NACT.
| Risks | PFS |
OS |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| HALP index cutoff score ≤ 22.6 | 2.92 | 1.58 - 5.40 | 0.001 | 2.66 | 1.57 - 4.49 | < 0.001 |
| Residual tumor ≥ 1 cm | 2.02 | 1.15 - 3.56 | 0.015 | 2.48 | 1.47 - 4.20 | 0.001 |
| VTE, yes | 4.99 | 2.65 - 9.40 | < 0.001 | 2.08 | 1.23 - 3.54 | 0.007 |
| ECOG performance status > 2 | 6.34 | 3.39 - 11.87 | < 0.001 | 7.79 | 4.72 - 12.88 | < 0.001 |
| NLR ≥ 3 | 2.74 | 1.56 - 4.83 | < 0.001 | 3.36 | 2.05 - 5.50 | < 0.001 |
| FIGO stage IVA | 2.37 | 1.09 - 5.18 | 0.029 | 3.34 | 1.96 - 5.70 | < 0.001 |
AEOC: advanced epithelial ovarian cancer; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; FIGO: International Federation of Gynecology and Obstetrics; HALP: hemoglobin-albumin-lymphocyte-platelet; HR: hazard ratio; NACT: neoadjuvant chemotherapy; NLR: neutrophil-to-lymphocyte ratio; OS: overall survival; PFS: progression-free survival; VTE: venous thromboembolism.